INT241799
From wiki-pain
|
|
|
|
|
Sentences Mentioned In
Key: | Protein | Mutation | Event | Anatomy | Negation | Speculation | Pain term | Disease term |
The level of chitinase decreased in the quebracho group. | |||||||||||||||
| |||||||||||||||
|
Two covariates affected the chitotriosidase decrease under ERT: splenectomy influenced the slope decline and genotype influenced the baseline level (Figure 2b). | |||||||||||||||
| |||||||||||||||
|
Chitotriosidase levels decreased, without reaching a normal level over a median of six (range, 0 to 15) years of follow-up. | |||||||||||||||
| |||||||||||||||
|
For patients given full-dose ERT, platelet counts increased slightly faster, ferritin and TRAP decreased faster, but chitotriosidase and ACE declined more slowly. | |||||||||||||||
| |||||||||||||||
|
During ERT, clinical abnormality rates decreased (except for neurological involvement) and the biological data improved overall during ERT (increased hemoglobin, leukocyte and platelet levels; decreased chitotriosidase, ACE, TRAP, ferritin and gammaglobulin levels). | |||||||||||||||
| |||||||||||||||
|
Platelet counts in nonsplenectomized patients were stable before ERT (+190 platelets/year), while chitotriosidase and TRAP decreased slightly, and ferritin and ACE increased slightly. | |||||||||||||||
| |||||||||||||||
|
For some biomarkers, not all patients had the same evolution under ERT: for example, platelet counts rose in 97% of treated patients, while chitotriosidase decreased in 100% and ferritin in 96%, but ACE levels in only 78%.
| |||||||||||||||
| |||||||||||||||
|
At 6 months, the previously untreated group showed a mean increase in hemoglobin of 0.77 g/dL, platelet count of 41.5 × 109/L or remained stable, and a mean decrease in their chitotriosidase levels of 38.2% (Table 1). | |||||||||||||||
| |||||||||||||||
|
Chitotriosidase levels decreased by 25.4% over 2 years (Table 1). | |||||||||||||||
| |||||||||||||||
|
After a total of 12 months treatment, spleen and liver volumes, and chitotriosidase levels decreased by only 10%, 6%, and 15%, respectively (Table 1). | |||||||||||||||
| |||||||||||||||
|
Unlike recombinant enzymes, SRT agents are small molecules that can cross the blood-brain barrier.59 Although improved pulmonary function, and a significant decrease in chitotriosidase levels have been observed in patients with GD type 3, miglustat unfortunately, does not appear to have any significant benefits on the neurological manifestations of GD.60 | |||||||||||||||
| |||||||||||||||
|
During ERT, clinical abnormality rates decreased (except for neurological involvement) and the biological data improved overall during ERT (increased hemoglobin, leukocyte and platelet levels; decreased chitotriosidase, ACE, TRAP, ferritin and gammaglobulin levels). | |||||||||||||||
| |||||||||||||||
|
After a total of 12 months treatment, spleen and liver volumes, and chitotriosidase levels decreased by only 10%, 6%, and 15%, respectively (Table 1). | |||||||||||||||
| |||||||||||||||
|
General Comments
This test has worked.